(Q36309415)

13 August 2017

1 reference

title

Vaccines against typhoid fever (English)

1 reference

13 August 2017

Carlos A Guzman

1

1 reference

13 August 2017

Stefan Borsutzky

2

1 reference

13 August 2017

Monika Griot-Wenk

3

1 reference

13 August 2017

Ian C Metcalfe

4

1 reference

13 August 2017

Jon Pearman

5

1 reference

13 August 2017

Andre Collioud

6

1 reference

13 August 2017

Didier Favre

7

1 reference

13 August 2017

Guido Dietrich

8

1 reference

13 August 2017

language of work or name

English

0 references

publication date

19 September 2005

1 reference

13 August 2017

1 reference

13 August 2017

24

1 reference

13 August 2017

18

1 reference

13 August 2017

3804-3811

1 reference

The molecular mechanisms of severe typhoid fever.

13 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Multi-drug resistant typhoid: a global problem.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Laboratory-based surveillance of Salmonella serotype Typhi infections in the United States: antimicrobial resistance on the rise

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

An analysis of economic costs associated with an outbreak of typhoid fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

A seven-year field trial of two typhoid vaccines in Guyana

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Effect of a Vi-degrading Enzyme on Potency of Typhoid Vaccines in Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Experience with Salmonella typhi Vi capsular polysaccharide vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Protective activity of Vi capsular polysaccharide vaccine against typhoid fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

A new typhoid vaccine composed of the Vi capsular polysaccharide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

The mucosal immune system: from fundamental concepts to vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Recent advances with recombinant bacterial vaccine vectors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Can needle-free administration of vaccines become the norm in global immunization?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Attenuated, Streptomycin-Dependent Salmonella typhi Oral Vaccine: Potential Deleterious Effects of Lyophilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Isolation and Characterization of Gal E Mutant Ty 21a of Salmonella typhi: A Candidate Strain for a Live, Oral Typhoid Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Virulence and vaccine potential of Salmonella typhimurium mutants deficient in the expression of the RpoS (sigma S) regulon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Experience with registered mucosal vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Characterization of CD8(+) effector T cell responses in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Clinical and immunological response to typhoid vaccination with parenteral or oral vaccines in two groups of 30 recruits.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Intracellular bacteria as targets and carriers for vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Chilean Typhoid Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Host-Salmonella interaction: human trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Compliance With Live, Oral Ty21a Typhoid Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Urgent need for effective vaccine against Salmonella paratyphi A, B and C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

Progress in vaccines against typhoid fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

inferred from DOI database lookup

7 January 2021

based on heuristic

Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

inferred from DOI database lookup

7 January 2021

based on heuristic

Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.111

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2005.07.111

1 reference

13 August 2017

1 reference